Your session is about to expire
← Back to Search
Observational (Project: Every Child) for Pheochromocytoma
N/A
Recruiting
Led By Douglas Hawkins
Research Sponsored by Children's Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
Summary
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Eligible Conditions
- Pheochromocytoma
- Cancer
- Neoplasm
- Stromal Neoplasm
- Carcinoma
- Brain Tumor
- Childhood Teratoma
- Langerhans Cell Histiocytosis
- Mature Teratoma
- Congenital Mesoblastic Nephroma
- Desmoid Tumor
- Ganglioneuroma
- Lymphoproliferative Disorders
- Melanoma
- Myeloproliferative Neoplasms
- Neuroendocrine Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of patients who consented to biobanking
Trial Design
1Treatment groups
Experimental Treatment
Group I: Observational (Project: Every Child)Experimental Treatment2 Interventions
Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal swab, saliva, cerebrospinal fluid, or urine).
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,841 Previous Clinical Trials
40,969,815 Total Patients Enrolled
23 Trials studying Pheochromocytoma
2,054 Patients Enrolled for Pheochromocytoma
Children's Oncology GroupLead Sponsor
457 Previous Clinical Trials
206,830 Total Patients Enrolled
Douglas HawkinsPrincipal InvestigatorChildren's Oncology Group
Share this study with friends
Copy Link
Messenger